Integrating Advances and Optimizing Contemporary Strategies in Renal Cell Carcinoma
E-publication E-publication

Integrating Advances and Optimizing Contemporary Strategies in Renal Cell Carcinoma


Released:
12/9/2016
Expires:
12/8/2017

Maximum Credits:

0.5

E-publication E-publication
Released:
12/9/2016

Expires:
12/8/2017

Maximum Credits:
0.5
E-publication E-publication

Released:
12/9/2016
Expires:
12/8/2017


Maximum Credits:
0.5


Overview: This CME-certified publication reviews the treatment options for patients with metastatic renal cell carcinoma (mRCC), discusses the latest clinical evidence for available therapeutic options, and explores the patient- and disease-related factors that should be considered when planning mRCC treatment.

CME Information:

Faculty
Robert J. Motzer, MD
Attending Physician
Department of Medicine
Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Activity Planners
Christie Avraamides, PhD
Clinical Content Manager
Med-IQ
Baltimore, MD

Rebecca L. Julian, MS, ELS
Senior Managing Editor
Med-IQ
Baltimore, MD

Amy Sison
Director of Continuing Medical Education
Med-IQ
Baltimore, MD

Writer
Anne Jacobson, MPH, CHCP, CMPP
Cocoa Beach, FL

Learning Objectives
Upon completion, participants should be able to:

  • Incorporate current guideline recommendations, patient- and disease-related factors, and clinical evidence into decisions about treatment selection and sequencing for multiple lines of therapy in mRCC
  • Implement strategies to effectively monitor for and manage treatment-related side effects

Target Audience
This activity is intended for oncologists.

Series Overview/Statement of Need
Since December 2005, the United States (US) Food and Drug Administration (FDA) has approved 10 new agents with diverse mechanisms of action for use in patients with metastatic renal cell carcinoma (mRCC). Advances in targeted therapy for mRCC have extended survival and increased the number of patients who are eligible for 2 or 3 lines of therapy. As a result, it is critical to plan across the continuum of care, with the choice of initial therapy affecting options for later treatment. The goals of optimal treatment sequencing are to maximize long-term response, minimize side effects, and preserve quality of life. Although the availability of multiple agents has expanded treatment options and improved the outlook for patients with mRCC, oncologists face a challenge when trying to appropriately and safely integrate newer agents into treatment plans.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
This CME activity consists of a 0.5-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Original Release Date: December 9, 2016
Expiration Date: December 8, 2017
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.?

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Robert J. Motzer, MD
Consulting fees/advisory boards: Eisai Inc., Exelixis, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Contracted research: Bristol-Myers Squibb, F. Hoffman La-Roche Ltd., Genentech, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

The writer, peer reviewers, and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or e-mail info@med-iq.com.

Hardware/Software Requirements
Operating System
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer

Browser
Microsoft Internet Explorer 8.0 or later

Mozilla Firefox - latest version
Download: http://www.mozilla.org/en-US/firefox/new/

Google Chrome - latest version
Download: http://www.google.com/chrome

Apple Safari - latest version
Download: http://www.apple.com/safari/download/

PDF Viewer
Adobe Acrobat Reader® or Adobe Reader
Download: http://get.adobe.com/reader/

Adobe Flash Player
Adobe Flash Player 9 or later
Download: http://get.adobe.com/flashplayer/

For technical support, go to https://www.med-iq.com/support-manual.html.

ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: https://www.Med-IQ.com/privacy-statement/.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Bristol-Myers Squibb.

Copyright
© 2016 Med-IQ®. All rights reserved.

 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.

Our website uses cookies to improve your experience. To learn more about the cookies we use, please visit our Privacy Notice and Terms of Use.